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 Abstract   
Ovarian cancers pose the greatest challenge for gynecological oncology. They are a heterogeneous, rapidly pro-
gressing and highly lethal group of malignancies and their etiology is still poorly understood. 
Among many hypotheses, explaining the pathogenesis of malignant tumors, chronic inflammation seems to play a 
significant role, which was proved in cervical, hepatic and esophageal cancers. The processes of inflammation and 
carcinogenesis are very much alike. Their similarity was experimentally confirmed by epidemiological, immunologi-
cal, biochemical and genetic studies. 
Additionally, this view is supported by indirect epidemiological and clinical evidence linking ovarian cancer with 
pelvic inflammatory disease, endometriosis or polycystic ovary syndrome. Chronic inflammation is a key factor in the 
pathogenesis of these illnesses. Moreover, ovulation involving repeated damage and repair of the ovarian surface 
epithelium is in fact an inflammatory process. 
In this review, we focus on the role of inflammation in cancer initiation, promotion and progression with special 
emphasis on the ovarian cancer. We discuss the potential involvement of the fallopian tubes, endometriosis and mi-
croenvironment of tumors represented by cytokines, chemokines, growth factors and various enzymes that destroy 
the extracellular matrix. Considering that molecular biology is currently rapidly evolving, we focus on the function of 
the mammalian target of rapamycin (mTOR) kinase and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) in the pathophysiology of inflammation and cancer.
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Introduction
Ovarian	 cancers	 are	 the	 second	 (after	 endometrial	 cancer)	
most	 common	group	of	 gynecologic	 cancers.	According	 to	 the	
data	reports	from	the	National	Cancer	Registry,	there	were	3474	
new	cases	of	ovarian	cancer	in	Poland	in	2009.	Therefore,	it	is	the	
sixth	most	 common	malignancy	 among	women	 following	 bre-
ast,	 lung,	colon,	skin	and	endometrial	cancer	with	an	estimated	
204	000	new	cases	and	125	000	deaths	per	year	worldwide	[1].
The	five-year	survival	rate	for	ovarian	cancer		is	as	low	as	
30%,	consequently,	it	is	one	of	the	leading	causes	of	cancer	de-
aths	among	women	 [2].	The	most	common	ovarian	cancer	ari-
ses	from	the	ovarian	surface	epithelium.	It	is	estimated,	that	ap-
proximately	90	to	95%	of	all	ovarian	malignancies	are	epithelial	
cancers.	The	development	of	cancer	from	the	ovarian	epithelium	
explains	the	strong	tendency	to	early	peritoneal	spread	and	asci-
tes	[3].	There	are	many	theories	explaining	the	pathogenesis	of	
ovarian	cancer,	including	the	chronic	inflammation,	which	seems	
to	play	a	significant	role.	Despite	extensive	scientific	research	in	
this	field,	molecular	mechanisms	correlating	carcinogenesis	and	
inflammation,	are	still	poorly	understood.
Pathogenesis of ovarian cancer
A	number	of	theories	have	been	proposed	to	explain	the	cau-
ses	of	ovarian	cancer.	The	most	widely	accepted	is	the	Fathalla's	
'incessant	ovulation'	hypothesis	with	repeated	damage	of	the	ova-
rian	 surface	 epithelium	 [4].	The	 known	 risk	 factors	 of	 ovarian	
cancer	–	nulliparity,	early	menarche,	late	menopause	and	the	use	
of	 hormonal	 contraceptive	pills	 (reducing	 the	 incidence	of	 this	
disease),	support	the	Fathalla’s	theory.	The	ovulation	process	is	
accompanied	by	formation	of	ovarian	inclusion	cysts	containing	
surface	epithelial	cells.	These	cells	are	exposed	to	various	auto-
crine	and	paracrine	agents	such	as	hormones,	phospholipids	eico-
sanoids	and	cytokines	exerting	stress	and	causing	damage.
Another	 theory	 assumes	proliferative	 and	mutagenic	 influ-
ence	 of	 high	 levels	 of	 gonadotropins	 during	 ovulation	 and	 in	
postmenopausal	women	[5].	Proliferative	effect	of	androgens	and	
progesterone	may	also	contribute	to	the	development	of	this	di-
sease	[6].
Inflammation and carcinogenesis
Acute	inflammation	is	a	protective	tissue	response	to	injury	
or	 destruction,	which	 serves	 to	 destroy	 the	 injurious	 agent	 and	
heal	injured	tissues.	Under	normal	physiological	conditions	it	re-
solves	 spontaneously	 after	 restoring	 the	 tissue	 architecture	 and	
function.	Various	pathological	states	such	as	persistent	infection	
or	 immunological	deficiency	can	 lead	 to	chronic	 inflammation,	
resulting	 in	 tissue	 injury	and	carcinogenesis.	The	possible	rela-
tionship	between	inflammation	and	cancer	was	first	mentioned	in	
1863	by	Rudolf	Virchow.	He	observed	the	infiltration	of	leukocy-
tes	in	neoplastic	tissues.	Over	half	a	century	later,	Harold	Dvorak	
made	a	hypothesis,	 that	 the	basic	developmental	mechanism	of	
both,	inflammation	and	carcinogenesis,	is	angiogenesis	and	that	
tumors	are	“wounds	that	do	not	heal”.	Chronic	inflammation	has	
been	proven	to	be	a	key	factor	in	pathogenesis	of	various	mali-
gnancies,	 such	 as	 primary	 liver	 cancer	 resulting	 from	hepatitis	
C	virus	infection,	esophageal	cancer	and	Helicobacter	pylori	in-
fection	or	 cervical	 cancer	 and	human	papillomavirus	 infection.	
Growing	body	of	evidence	supports	the	theory	that	non-steroidal	
anti-inflammatory	 drugs	 (NSAIDs),	 especially	 aspirin,	 protect	
against	cancer	[6].	
The	developmental	mechanisms	of	inflammation	and	carci-
nogenesis	are	very	complex.	Inflammation	influences	all	stages	
of	 cancer	 formation	 i.e.	 initiation,	promotion	and	 	progression.	
Various	inflammatory	mediators	participate	in	the		formation	of	
cancers	acting		as	growth	factors	or	angiogenic	factors.	There	are	
many	potentially	effective	anticancer	drugs	directed	at	 	pro-in-
flammatory	cytokines,	such	as,	IL-6	or	TNF-α.	Moreover,	reac-
tive	oxygen	species	(ROS)	along	with	reactive	nitrogen	species	
(RNS)	greatly	contribute	to	carcinogenesis	by	inducing	a	cellular	
redox	imbalance	which	has	been	found	in	various	cancer	cells	[8].	
 Streszczenie
Nowotwory jajnika są  największym wyzwaniem w onkologii ginekologicznej. Stanowią heterogenną, gwałtownie 
postępującą oraz wysoce śmiertelną grupę guzów, których etiologia ciągle jest w znikomym stopniu poznana.
Wśród wielu hipotez wyjaśniających patogenezę nowotworów przewlekłe zapalenie wydaje się odgrywać zasad-
niczą rolę, co udowodniono w przypadku raka szyjki macicy, wątroby czy przełyku. Stan zapalny i kancerogeneza 
to w istocie bardzo podobne do siebie procesy, zostało to doświadczalnie potwierdzone na gruncie epidemiologii, 
immunologii, biochemii czy genetyki. Pośrednich dowodów, iż rak jajnika związany jest z przewlekłymi procesami 
zapalnymi dostarczają dane epidemiologiczne i kliniczne wiążące ten nowotwór z PID (stan zapalny narządów 
miednicy mniejszej) endometriozą czy zespołem policystycznych jajników. W etiologii tych schorzeń stan zapalny 
odgrywa dominującą rolę. 
Dodatkowo proces owulacji polegający na cyklicznym uszkadzaniu i odtwarzaniu nabłonka pokrywającego jajnik 
ma w istocie podłoże zapalne. 
W naszej pracy skupiliśmy się na roli jaką proces zapalny odgrywa w inicjacji, promocji i progresji nowotworów ze 
szczególnym uwzględnieniem raka jajnika. Omówiona została potencjalna rola jajowodów, endometriozy oraz mi-
krośrodowska guza reprezentowanego przez cytokiny, chemokiny, czynniki wzrostu czy enzymy niszczące macierz 
pozakomórkową. Szczególną rolę położono na intensywnie rozwijające się badania molekularne i rolę kinazy mTOR 
oraz czynnika transkrypcyjnego NF-kappaB.
 Słowa kluczowe: rak jajnika / rak jajowodu / zapalenie /endometrioza / 
     / karcynogeneza /
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The	significance	of	immune	system	in	the	formation	of	can-
cer	is	still	poorly	understood.	On	one	hand,	the	immunosuppres-
sion	enables	the	cancer	cells	to	evade	detection,	and	on	the	other,	
the	immune	system	forms	a	barrier	against	carcinogenesis.	The	
most	 recent	 research,	 has	 provided	 evidence,	 that	many	 genes	
involved	 in	 the	development	of	cancer	 show	activity	 in	 the	 in-
flammatory	processes.	They	act	as	modulators	of	immune	respon-
se	in	the	way	that	facilitates	the	formation	of	cancer.	
Inflammation and ovarian cancer
Ovarian	 cancer	 arises	 mainly	 from	 the	 ovarian	 surface	
epithelium.	Due	to	the	specific	location	of	the	ovarian	epithelial	
cells	in	the	peritoneal	cavity	they	are	distinctly	exposed	to	various	
pro-inflammatory	agents.	There	are	various	sources	of	this	type	of	
inflammation.	It	has	been	found	that	ovulation	itself	is	a	process	
of	potentially	inflammatory	and	mutagenic	character	[7].	During	
ovulation,	epithelial	cells	in	the	immediate	vicinity	of	the	ovarian	
follicle	undergo	extensive	proliferation,	destruction	and	apopto-
sis,	resulting	in	the	rupture	of	the	follicle	wall	and	subsequent	re-
modeling	and	repair.	It	is	postulated	that	this	sequential	course	of	
action	causes	oxidative	stress	through	increased	concentration	of	
pro-inflammatory	mediators	such	as	cytokines,	interleukins,	gro-
wth	 factors,	prostaglandins	and	eicosanoids	 [8].	Another	 factor	
which	links	ovulation,	inflammation,	tumor	growth	and	spread	is	
the	activity	of	collagenases,	enzymes	that	destroy	the	extracellu-
lar	matrix.	The	repeated	cycles	of	cellular	damage	and	repair	in	
highly	oxidative	environment	favor	errors	during	DNA	replica-
tion.	 In	 patients	with	 ovarian	 cancer,	 the	 peritoneum,	 covering	
most	of	the	intra-abdominal	organs,		shows	macroscopic	manife-
stations	typical	of	inflammation	such	as	swelling,	redness,	incre-
ased	density	of	blood	vessels,	adhesions	or	ascites	[7].	Ovarian	
cancer	risk	is	positively	associated	with	increasing	serum	levels	
of	CRP	which	further	supports	the	theory	relating	ovarian	cancer	
to	chronic	inflammation	[9].	Previously	mentioned	preventive	in-
fluence	of	NSAIDs	depends	on	the	suppression	of	transcription	
factor	NF-kappaB.	It	is	a	protein	complex	that	controls	the	tran-
scription	of	DNA	and	plays	a	key	role	in	controlling	the	immune	
response	 to	 infection	 as	well	 as	 cell	 proliferation	 and	 survival.	
The	increased	activity	of	NF-kappaB	is	observed	in	both,	the	in-
flammatory	states	and	a	considerable	percentage	of	all	cancers.	
NF-kappaB	inactivation	leads	to	lower	concentration	of	growth	
factors,	adhesive	molecules,	apoptosis	regulators,	cytokines	and	
chemokines	(COX-2,	VEGF,	IL-8/CXCL8,	MCP-1/CCL-2,	MI-
P1alpha/CCL-3,	 tPA	and	Upa),	which	 suppresses	angiogenesis,	
invasion	and	 resistance	 to	apoptosis	 [7]	 (Figure	1).	Techniques	
aimed	at	the	inactivation	of	NF-kappaB	are	successfully	used	in	
the	treatment	of	chronic	inflammatory	diseases	and	are	a	promi-
sing	direction	in	the	treatment	of	cancer	[10].
 
 
Figure 1. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex. It controls transcription of DNA and plays an important role in 
inflammation, autoimmune response, apoptosis and cell proliferation. NF-κB can be found in almost all eukaryotic cells. It is homo- or heterodimer of different subunits, in this 
case p50 and p65. In the cytoplasm of unstimulated cells NF-κB is bound to regulatory proteins called inhibitors of κB (IκB). Stimulation of cells leads to proteolytic degradation 
of IκB by the enzyme IκB kinase (IKK) and therefore activation of NF-κB. After translocation into the nucleus, NF-κB forms a complex with RNA polymerase (RNAP), coactivators 
(CoA) and DNA. The complex leads to transcription of DNA to mRNA..
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Ovarian and fallopian tube cancer
Pathology	findings	in	reviewed	specimens	from	BRCA	muta-
tion	carriers	after	prophylactic	and	risk-reducing	salpingo-oopho-
rectomy	revealed	precursor	lesions	and	foci	of	highly	differentia-
ted	serous	carcinoma	in	fallopian	tubes	[11,	12].	These	changes	
were	almost	exclusively	located	in	the	distal	or	fimbriated	end	of	
the	fallopian	tube	[13].	This	observation	leads	to	a	conclusion	that	
at	least	some	percentage	of	the	highly	malignant	ovarian	cancers	
may	originate	from	the	fallopian	tubes.	These	structures	are	the	
point	of	contact	for	ciliated	columnar	epithelium	lining	the	lumen	
of	the	uterine	tubes	and	mesothelium	covering	the	peritoneal	ca-
vity.	The	site	of	their	contact	is	especially	prone	to	inflammation	
and	 damage,	which	was	 confirmed	 in	 the	 case	 of	 cervical	 and	
esophageal	carcinoma	[14].	Oviduct	is	an	organ	particularly	lia-
ble	 to	 inflammation.	Pathogens	most	 frequently	 found	here	are	
Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma 
hominis,	 as	 well	 as	 other	 aerobic	 and	 anaerobic	 bacteria	 [15].	
Adnexitis	has	been	proven	to	be	one	of	the	causative	factors	of	
ovarian	cancer	 [16].	Authors	assessed	 the	 risk	of	ovarian	mali-
gnancy	in	a	group	of	patients	with	pelvic	inflammatory	disease	to	
be	2.78	per	10,000	person-years,	as	compared	to	an	incidence	of	
1.44	per	10,000	person-years	in	patients	from	the	control	group.	
They	also	found,	that	the	hazard	ratio	was	highest	among	women	
who	have	had	multiple	episodes	of	PID.	Chemicals	such	as	asbe-
stos	or	talc	commonly	used	for	intimate	hygiene	also	contribute	
to	fallopian	tube	damage	and	cell	transformation	[17].	One	of	the	
most	significant	factors	repeatedly	irritating	the	epithelial	lining	
of	the	uterine	tubes	is	a	retrograde	flow	of	menstrual	blood,	rich	in	
particles	having	oxidative	properties	such	as	heme	and	iron	[18].	
This	mechanism	is	 the	most	widely	accepted	 theory	explaining	
the	 pathogenesis	 of	 endometriosis,	 uterine	 tubes	 inflammation	
and	cancer.	Chronic	 inflammation	 is	often	observed	 in	 the	ovi-
ducts	surgically	removed	from	patients	with	ovarian	cancer	[19].	
In the study by Seidman et al.,	50%	of	fallopian	tubes	removed	
from	women	with	ovarian	malignancy	showed	inflammation,	as	
compared	with	27%	obtained	 from	noncancerous	patients.	The	
protective	 effect	 of	 hysterectomy	 provides	 further,	 albeit	 in-
direct,	evidence	that	retrograde	spillage	of	menstrual	blood	plays	
an	important	role	in	the	ovarian	carcinogenesis	[20].	These	ob-
servations	lead	to	a	conclusion,	that	during	removal	of	the	uterus	
performed	due	to	benign	conditions	such	as	myomas,	in	patients	
wishing	to	retain	ovaries,	bilateral	salpingectomy	should	be	con-
sidered	in	order	to	lower	the	risk	of	ovarian	carcinoma.
 
 
Figure 2. Conserved seronine/threonine kinase mTOR integrates the input from upstream pathways, including mitogens, growth factors and hormones. mTOR enhances 
translation initiation in part by phosphorylating two major targets: the 4E-BP1 (inhibitory 4E-binding protein) family of proteins and ribosomal protein S6 kinases (for example 
oncogene S6K1). By phosphorylating the 4E-BP1, a well established tumor suppressor, mTOR represses its capacity to inhibit the mRNA cap-binding protein transcription 
factor eIF4E - a known potent oncogene. Translation is also prompted by activated S6K1, which co-operates to regulate gene expression and translation processes, particularly 
the translation of proteins encoded by 5’terminal oligopyrimide (5’TOP) genes. On the other hand, activation of AKT is physiologically prevented by a gene product of tumor 
suppressor PTEN (phosphatase and tensin homologue deleted from chromosome 10), a phosphatase that removes the phosphate attached by PI3K from PIP3. AKT protein 
is also an indirect positive regulator of mTOR through the phosphorylation and inactivation of mTOR inhibitors, such as protein products of the TSC1 and TSC2 genes - well 
established tumor suppressors. Tumor suppressor genes LKB1, p53, NF1 also, albeit indirectly regulate the activity of mTOR. 
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Ovarian cancer and endometriosis 
Endometriosis	 is	 a	 chronic,	 benign	 inflammatory	 disease,	
affecting	millions	of	women	of	reproductive	age	throughout	the	
world.	There	 is	a	great	amount	of	epidemiological	and	histolo-
gical	data	linking	the	incidence	of	this	disease	with	endometrial	
and	ovarian	clear	cell	carcinoma	[21].	The	group	of	endometrio-
sis-associated	ovarian	cancers	(EAOC)	is	characterized	by	relati-
vely	low	malignant	potential	and	high	detection	rate	in	their	early	
stages.	It	was	demonstrated,	that	the	uninterrupted	menstrual	cyc-
le	is	a	common	risk	factor	for	endometriosis	and	ovarian	carci-
noma	[22].	Chronic	 inflammation	and	sex	hormones	acting	via	
autocrine	or	paracrine	mechanisms,	 seem	to	play	a	crucial	 role	
in	 carcinogenesis	 [23].	A	 broad	 spectrum	of	 cytokines,	 growth	
factors	and/or	matrix	metalloproteinases	released	with	the	occu-
rrence	of	endometrial	lesions	stimulate	mitotic	activity,	angioge-
nesis,	growth,	differentiation,	migration	and	apoptosis	[24,	25].	
The	inflammatory	milieu	favors	genetic	modifications	of	ectopic	
endometrial	implants,	which	may	eventually	lead	to	cancer.	Mo-
lecular	analysis	of	endometrial	and	neoplastic	tissues	confirmed	
the	presence	of	similar	genetic	abnormalities	in	both	endometrio-
sis	and	ovarian	carcinoma.	Among	them,	loss	of	heterozygosity	
(LOH)	on	chromosomes	1p,	9p,	1lq,	17p	and	22q,	amplification	
at	17q,	mutations	of	oncogenes	(e.g.	K-ras)	and	PTEN	tumor	sup-
pressor	genes,	as	well	as	overexpression	of	selected	genes	related	
to	mammalian	target	of	rapamycin	(mTOR)	pathway	are	detec-
ted	[26,	27].	Mutation	of	p53	suppressor	gene	is	one	of	the	most	
frequently	encountered	aberration	in	endometrial	and	neoplastic	
tissues.	Disturbed	 function	 of	p53	 results	 in	 excessive	 cellular	
proliferation	 and	 inhibition	 of	 apoptosis.	 Kinase	 mTOR	 plays	
a	important	role	in	pathogenesis	of	ovarian	cancer	and	endome-
triosis,	and	is	responsible	for	regulation	of	cell	proliferation	and	
growth.	High	 activity	 of	mTOR,	 especially	 in	 postmenopausal	
women,	was	confirmed	by	analysing	specimens	taken	from	en-
dometrial	lesions	and	ovarian	cancer	[28].	This	protein	integrates	
the	 input	 from	upstream	pathways	 including	hormones,	growth	
factors,	 mitogens	 and	 nutrients.	 Interactions	 between	 various	
oncogenes	 and	 tumor	 suppressor	genes	 are	 shown	 in	Figure	2.	
Kinase	mTOR	inhibitors	are	successfully	applied	as	immunosup-
pressive	agents.	Ongoing		scientific	research	will	explain	whether	
these	drugs	are	beneficial	 in	 the	treatment	of	 tuberous	sclerosis	
and	cancer.	The	efficacy	of	temsirolimus,	an	mTOR/AKT	inhibi-
tor,	was	confirmed	in	the	successful	treatment	of	deep	infiltrating	
endometriosis	 in	mice,	 and	 therefore,	 it	may	offer	 a	 promising	
therapy	to	be	applied	in	humans	[29].	
Summary
Malignant	 neoplastic	 diseases	 remain	 one	 of	 the	 greatest	
challenges	 in	 the	 twenty-first	 century	 science.	 Despite	 the	 im-
mense	progress	in	medicine	over	the	recent	years	their	pathophy-
siology	remains	unclear	in	many	aspects	and	calls	for	even	more	
efforts.	Among	many	factors	contributing	to	cancer	development,	
chronic	inflammation	seems	to	play	a	significant	role.	Understan-
ding	these	processes	will	result	in	the	introduction	of	new	thera-
pies	improving	the	outcomes	of	treatment.	
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